Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass. , jan. 2, 2025 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted a stock option to purchase an aggregate of 101,250 shares of karyopharm's common stock and an aggregate of 108,540 restricted stock units (rsus) to four newly-hired employees.
KPTI Ratings Summary
KPTI Quant Ranking